https://www.fiercepharma.com/ a feed of the latest articles on our website en https://www.fiercepharma.com/pharma/trumps-pharma-holdings-boomed-medicare-price-negotiation-carveouts-democrats-allege As midterms loom, Democrats on Congress’ Joint Economic Committee (JEC) are reviving concerns about the orphan drug carveout tucked into Republicans’ One Big Beautiful Bill Act, alleging that President Donald Trump accumulated millions of dollars in pharma stocks before and after the enactment of policies benefiting some of those same companies. Oct 16, 2026 2:51pm Fraiser Kansteiner https://www.fiercepharma.com/dd7e60e2-9e90-429d-bd05-04a3b500d073 https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions. Apr 21, 2026 10:06am Angus Liu, Kevin Dunleavy, Fraiser Kansteiner, Donavyn Coffey https://www.fiercepharma.com/95fc1f29-4c60-4c4e-85a1-7e3739ee4672 https://www.fiercepharma.com/pharma/lillys-obesity-pill-revmeds-pancreatic-cancer-breakthrough-among-slew-chmp-endorsements Across the pond, European regulators handed down a pair of pivotal approval recommendations this week, making way for a new front in Novo and Eli Lilly’s oral GLP-1 showdown and endorsing Revolution Medicines’ potential pancreatic cancer game changer. Oct 16, 2026 11:15am Fraiser Kansteiner https://www.fiercepharma.com/724538c1-871c-460e-b5a4-587dda81b683 https://www.fiercepharma.com/marketing/sanofi-cycles-deeper-athletic-marketing-niche-tour-de-france-partner The French pharma will sponsor the prestigious white jersey, awarded to the best rider under 25, at both the Tour de France and the Tour de France Femmes in 2027. Oct 16, 2026 11:31am Zoey Becker https://www.fiercepharma.com/2cd259de-ad05-435d-97a5-439f99bebaad https://www.fiercepharma.com/biotech/china-looks-ban-foreign-acquisitions-critical-biopharma-platforms As Washington ramps up efforts to tighten cross-border life sciences deals involving Chinese assets, Beijing is moving to tighten its own grip on biomedical innovation, rolling out a draft policy that would ban or restrict the export of key biopharmaceutical technologies. Oct 16, 2026 10:40am Angus Liu https://www.fiercepharma.com/f7b426d0-dc10-4271-92c6-0d8b7f6252ce https://www.fiercepharma.com/pharma/inside-tevas-weltruza-launch-and-novos-glp-1-strategy This week on "The Top Line," we catch up with leaders from Teva and Novo to discuss new drug launches, growth opportunities and what's ahead for both companies. Oct 16, 2026 9:33am Ayla Ellison, Fraiser Kansteiner, Zoey Becker https://www.fiercepharma.com/98727656-c0db-47ac-a438-c5a27549079e https://www.fiercepharma.com/pharma/roche-makes-class-first-push-thyroid-eye-disease-new-fda-nod-enspryng Some six years after scoring an initial FDA nod, Roche’s IL-6 receptor inhibitor Enspryng is muscling up to Amgen's Tepezza in a key eye disease arena. Oct 16, 2026 9:29am Fraiser Kansteiner https://www.fiercepharma.com/4ba915ec-6e48-400a-bab1-b13e4f6872f9 https://www.fiercepharma.com/pharma/roche-12b-obesity-deal-asahi-kasei-fda-nod-verastem-kras-boon Roche extended its China shopping spree with a $1 billion-plus obesity deal. Asahi Kasei's Hovilpri became the first HSV drug with a novel mechanism approved in nearly 30 years. Verastem's China-licensed KRAS G12D inhibitor showed strong early data in pancreatic cancer. And more. Oct 15, 2026 6:16pm Angus Liu https://www.fiercepharma.com/ab9805e4-8478-4c58-9603-261492fa249e https://www.fiercepharma.com/providers/hospital-industry-files-lawsuit-block-hhs-340b-rebate-pilot-again The American Hospital Association and others have launched a legal rematch with the federal government over the second iteration of a pilot program swapping out safety-net hospitals’ upfront drug discounts for after-the-fact rebates. Oct 9, 2026 11:01am Dave Muoio https://www.fiercepharma.com/d4c32a59-9f2a-4729-afd4-f14560375784 https://www.fiercepharma.com/pharma/kindeva-meridian-land-226m-defense-contract-supply-nerve-agent-antidote Kindeva's Meridian was awarded a $226 million defense contract to supply the U.S. military with its self-injected nerve agent antidote and bolster national defense against chemical threats. Oct 15, 2026 12:16pm Donavyn Coffey https://www.fiercepharma.com/a41b085f-2fa4-484f-9388-7303e3ab1412 https://www.fiercepharma.com/pharma/par-health-recalls-22-lots-iv-blood-thinner-its-3rd-recall-month Par Health issued a recall of 22 lots of the intravenous anticoagulant argatroban, the latest in a string of recent recalls related to IV-bag contamination risk. Oct 15, 2026 9:43am Donavyn Coffey https://www.fiercepharma.com/3e984475-664a-4d6a-bf18-86a3dfeb5bab https://www.fiercepharma.com/pharma/new-omvoh-analyses-lilly-argues-higher-bar-ibd-treatment-within-reach In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a holistic solution for patients living with ulcerative colitis or Crohn’s disease—and one that could offer relief after other biologic drugs have failed, too. Oct 15, 2026 10:48am Fraiser Kansteiner https://www.fiercepharma.com/d161df26-9752-4484-98e5-e9c5c83ff783 https://www.fiercepharma.com/marketing/gilead-puts-timely-spotlight-hiv-prevention-latino-communities-ahorita-mismo-campaign Gilead's “Ahorita Mismo (Right Now!)” stars two popular Latino creators in a call-in podcast-themed spot looking to spark conversations around HIV prevention. Oct 14, 2026 6:33pm Zoey Becker https://www.fiercepharma.com/365b6b1f-13bf-452d-83b6-e42a0fa23782 https://www.fiercepharma.com/pharma/isotope-supplier-northstar-continues-rise-partnership-tee-china-radiopharmaceutical-filings As the momentum continues to pick up at NorthStar Medical Technologies, the radioisotope producer is strengthening ties in China, in a move that helps put its actinium-225 supplies on the map for local radiopharmaceutical filings.  Oct 15, 2026 8:02am Fraiser Kansteiner https://www.fiercepharma.com/19bd4822-8086-4bbd-a97b-420c99c2b2cc https://www.fiercepharma.com/marketing/compass-puts-treatment-resistant-depression-map-first-awareness-day Compass Pathways has partnered with mental health organizations on the first-ever awareness day for treatment-resistant depression. Oct 15, 2026 5:51am Nick Paul Taylor https://www.fiercepharma.com/4030a1a3-526f-471f-b6b4-82bdca3139fe https://www.fiercepharma.com/pharma/fda-clears-immunitybio-anktiva-expansion-bladder-cancer-after-regulatory-whiplash To expand Anktiva’s label, the FDA adopted a new approach to how it evaluates treatments for BCG-unresponsive NMIBC. The new regulatory path essentially allowed ImmunityBio to bypass an expensive randomized phase 3 trial that competitor Johnson & Johnson is currently forced to grind through. Oct 14, 2026 4:54pm Angus Liu https://www.fiercepharma.com/e96b062b-6159-4105-b46a-79789cd6ad1d https://www.fiercepharma.com/pharma/ultragenyx-makes-swift-413m-return-fda-review-vouchers-after-summer-gene-therapy-nods Hot off a pair of key FDA approvals this summer, rare disease specialist Ultragenyx has wasted little time cashing in on the priority review vouchers it earned from the green lights. Oct 14, 2026 4:22pm Fraiser Kansteiner https://www.fiercepharma.com/42d3ad7d-7483-4fa5-8741-fbe2199cd069 https://www.fiercepharma.com/pharma/united-lands-clearcut-win-liquidia-agrees-380m-settlement-tyvaso-patent-infringement-saga With a years-long patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United Therapeutics has clinched what one analyst calls a “clear-cut win” over lung disease rival Liquidia Technologies. Oct 14, 2026 10:16am Fraiser Kansteiner https://www.fiercepharma.com/14c0398d-cd91-4286-8b68-d889d3e4bedd https://www.fiercepharma.com/pharma/galderma-bulks-dermatology-portfolio-15b-acquisition-zo-skin-health Expanding its presence in dermatology, Cetaphil maker Galderma has agreed to acquire professional skincare shop Zo Skin Health for $1.5 billion. Oct 14, 2026 10:04am Angus Liu https://www.fiercepharma.com/dd298db6-0b9c-4b02-9b05-3638bbd81ee9 https://www.fiercepharma.com/marketing/abbvie-marks-calendar-time-treks-national-parks-foundation-cll-society-partnership AbbVie's “Time For Treks” brings the chronic lymphocytic leukemia (CLL) community together for an outdoor gathering at Cabrillo National Monument, San Diego, on Oct. 17. Oct 14, 2026 10:11am Zoey Becker https://www.fiercepharma.com/1f1b9390-0b17-463d-b561-cda3144e1595 https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026-h2 In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. Jul 1, 2026 1:33pm Angus Liu, Kevin Dunleavy, Fraiser Kansteiner, Donavyn Coffey https://www.fiercepharma.com/a6f8f591-bb07-4a55-b9ca-16ca7271358a https://www.fiercepharma.com/pharma/martin-shkreli-defied-lifetime-pharma-ban-ftc-calls-sanctions The FTC alleges that “Pharma Bro” Martin Shkreli flagrantly traded pharmaceutical stocks on social media for three years, violating his lifetime ban from the industry. Oct 14, 2026 8:48am Donavyn Coffey https://www.fiercepharma.com/9dfb3f59-95a8-44ea-90a5-e99ab0257169 https://www.fiercepharma.com/pharma/nantworks-soon-shiong-puts-chips-behind-manufacturing-disruptors-new-rounds-prolific With demand for advanced manufacturing solutions mounting across the industry, the moment is ripe to capitalize on investor interest and build out toward a potential production paradigm shift. Oct 14, 2026 7:56am Fraiser Kansteiner https://www.fiercepharma.com/bb3be340-e33f-455c-8617-1ee2d1a065e7 https://www.fiercepharma.com/marketing/sanofi-dodges-eu-fine-over-alleged-disparagement-csl-flu-vaccine Sanofi has avoided a European Union fine after antitrust regulators accepted its commitments to address the alleged disparagement of CSL Seqirus’ rival flu vaccine. Oct 14, 2026 7:19am Nick Paul Taylor https://www.fiercepharma.com/36faef2c-24a0-4ad4-8ed4-84cbf3a59d55 https://www.fiercepharma.com/biotech/gsk-lay-over-12k-roles-belgium-cost-saving-program-picks-steam Up to 1,217 GSK employees in Belgium are at risk of losing their jobs as the Big Pharma rolls out its global cost-saving plans. Oct 14, 2026 6:39am James Waldron https://www.fiercepharma.com/e9678eb9-d37b-49db-8b5b-3725a746a96d